JW Pharmaceutical Participates in JP Morgan Healthcare Conference 2026

Discussion of Technology Partnerships for Key New Drug Pipelines

JW Pharmaceutical announced on January 20 that it participated in the 'JP Morgan Healthcare Conference 2026,' held in San Francisco, USA, from January 12 to 15 (local time), and conducted business development (BD) meetings with global pharmaceutical companies.

The JP Morgan Healthcare Conference is the world's largest healthcare investment event, bringing together major pharmaceutical, biotech companies, and investment institutions from around the globe every year.

Exterior view of JW Pharmaceutical headquarters in Gwacheon, Gyeonggi Province. JW Pharmaceutical

During this event, JW Pharmaceutical held numerous one-on-one meetings at the request of overseas pharmaceutical companies. In these meetings, the company discussed the potential for licensing out and technology partnerships regarding its key new drug pipelines, including: ▲JW0061, a candidate for hair loss treatment ▲JW1601, a treatment for ophthalmic diseases ▲and a STAT6 inhibitor-based treatment for inflammatory diseases.

JW0061 is a GFRA1 (glial cell line-derived neurotrophic factor family receptor alpha 1) agonist currently being developed for indications such as androgenetic alopecia. The compound recently obtained a U.S. patent and has also been submitted for an Investigational New Drug (IND) application to the Ministry of Food and Drug Safety.

JW1601, a histamine H4 receptor antagonist, has undergone a strategic review and its indication has been changed to a treatment for ophthalmic diseases. The company is currently preparing to enter Phase 2 clinical trials.

The STAT6 inhibitor is a 'first-in-class' oral innovative drug candidate targeting type 2 inflammatory diseases such as eosinophilic esophagitis (EoE). STAT6, in particular, is an emerging mechanism of action target attracting significant attention from the global pharmaceutical industry, and active research and development are underway for indications with limited treatment options. This research was selected as a national new drug development project for 2025.

A JW Pharmaceutical representative stated, "The JP Morgan Healthcare Conference is an important opportunity to directly discuss potential business collaborations with global pharmaceutical companies," adding, "We plan to continue seeking global partnership opportunities based on our research and development achievements."